康莱特联合吉非替尼对晚期非小细胞肺癌患者免疫功能和生活质量的影响

目的 评价康莱特联合吉非替尼对晚期非小细胞肺癌患者细胞免疫功能和生活质量的影响。方法 晚期非小细胞肺癌患者46例,依据治疗方法分为治疗组和对照组各23例,治疗组应用康莱特联合吉非替尼,对照组应用吉非替尼单药,2组均21d为1个周期。分别于治疗前、治疗2个周期后测定2组CD3、CD4、CD4/CD8和自然杀伤（natural killer,NK）细胞活性,并观察2组KPS评分和不良反应发生率。结果 治疗组治疗后CD3、CD4、CD4/CD8和NK细胞活性（（53.98±9.17）%、（35.89±7.96）%、1.69±0.49、（42.42±9.28）%）高于治疗前（（48.33±9.62）%、（30.92±8.67）%、1.35±0.62、（36.51±10.52）%）及对照组治疗后（（47.50±6.96）%、（29.30±8.60）%、1.26±0.57、（33.01±6.70）%）（P〈0.05）,对照组治疗前、后各指标比较差异无统计学意义（P〉0.05）;治疗组KPS评分改善＋稳定及体质量增加＋稳定百分率（82.6%、73.9%）高于对照组（52.2%、43.5%）（P〈0.05）;2组腹泻、皮疹发生率比较差异无统计学意义（P〉0.05）。结论 康莱特联合吉非替尼可提高晚期非小细胞肺癌患者的细胞免疫功能,改善患者生存质量,安全性好。

Influence of Kanglaite plus Gefitinib on immune function and quality of life in patients with advanced non-small cell lung cancer

Objective To evaluate the influence of Kanglaite plus Gefitinib on immune function and quality of life in patients with advanced non-small cell lung cancer. Methods Forty-six patients with advanced non-small cell lung cancer were divided into treatment group receiving Kanglaite plus Gefitinib and control group receiving Gefitinib, with 23 patients in each group, for 21 days as one cycle. The levels of CD3 and CD4, CD4/CD8 and natural killer （NK） cell activity were detected before and 2 cycles after treatment, and KPS scores and the incidences of adverse reaction were observed in two groups. Results The levels of CD3 and CD4, CD4/CD8 and NK cell activity were higher after treatment （（53.98±9.17） %, （35.89±7.96）%, 1. 69±0.49, （42.42±9. 28） %） than those before treatment in treatment group （（48.33±9.62） %, （30.92±8.67）%, 1.35±0.62, （36.51±10.52）%）, and after treatment in control group （（47.50±6.96） %,（29.30±8.60）%, 1.26±0.57, （33.01±6.70）%） （P〈0.05）, and did not change significantly in control group after treatment （P〉0.05）. The proportions of improved and stable KPS scores as well as increased body weight were higher in treatment group （82. 6%, 73. 9%） than those in control group （52.2%, 43. 5%） （P〉0.05）. There were no significant differences in the incidences of diarrhea and rash between two groups （P〉0.05）. ConcLusion Kanglaite plus Gefitinib can enhance the immune function for patients with advanced non-small cell lung cancer and improve the quality of life, and it is safe.